Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study.
Anti-drug antibodies
Bridging ELISA
Interferon-beta
Luciferase-based bioassay
Multiple sclerosis
Neutralizing antibodies
Journal
Journal of neuroimmunology
ISSN: 1872-8421
Titre abrégé: J Neuroimmunol
Pays: Netherlands
ID NLM: 8109498
Informations de publication
Date de publication:
15 01 2019
15 01 2019
Historique:
received:
09
07
2018
revised:
05
11
2018
accepted:
05
11
2018
pubmed:
18
11
2018
medline:
30
11
2019
entrez:
18
11
2018
Statut:
ppublish
Résumé
Two validated assays, a bridging ELISA and a luciferase-based bioassay, were compared for detection of anti-drug antibodies (ADA) against interferon-beta (IFN-β) in patients with multiple sclerosis. Serum samples were tested from patients enrolled in a prospective study of 18 months. In contrast to the ELISA, when IFN-β-specific rabbit polyclonal and human monoclonal antibodies were tested, the bioassay was the more sensitive to detect IFN-β ADA in patients' sera. For clinical samples, selection of method of ELISA should be evaluated prior to the use of a multi-tiered approach. A titer threshold value is reported that may be used as a predictor for persistently positive neutralizing ADA.
Identifiants
pubmed: 30447419
pii: S0165-5728(18)30332-1
doi: 10.1016/j.jneuroim.2018.11.002
pii:
doi:
Substances chimiques
Antibodies, Neutralizing
0
Immunologic Factors
0
Interferon-beta
77238-31-4
Types de publication
Comparative Study
Journal Article
Multicenter Study
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
19-27Informations de copyright
Copyright © 2018 Elsevier B.V. All rights reserved.